Overview

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single or multiple center study to determine the interaction of rifampin with navitoclax (ABT-263) in approximately 12 subjects with cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Abbott
AbbVie
Treatments:
Navitoclax
Rifampin